Humira nabs official EU nod for children with psoriasis; Daiichi's U.S. subsidiary merging with sister company;

@FiercePharma: Texas Tech scientists discover that antibiotic-resistant bugs from cattle lots are airborne. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Actavis execs up for $101M in merger-related bonuses, if investors approve. Story | Follow @CarlyHFierce

> AbbVie's ($ABBV) anti-inflammatory blockbuster Humira won European approval as a treatment for children with severe psoriasis. Report

> Daiichi Sankyo's U.S. subsidiary says it will merge with a U.S.-based sister company, Asubio Pharmaceuticals, and fold the latters R&D projects into its own development operation. Report

> British drugmaker BTG lifted its fiscal year forecast, saying it's looking for 345 million pounds, about $528 million, on the low end. Report

> Opioid misuse in patients with chronic pain is about 25%, according to a new study published in the journal PAIN. Report

Medical Device News

@FierceMedDev: Japanese researchers study carbon nanotubes with drug delivery applications. FierceDrugDelivery story | Follow @FierceMedDev

@StacyALawrence: ICYMI: App enabling iPhone to function as hearing aid launched. Article | Follow @StacyALawrence

@VarunSaxena2: Pilot program deploying COPD Navigator app launched with participation of Mount Sinai hospital. Story | Follow @VarunSaxena2

@EmilyWFierce: Check out this week's edition of FierceLifeSci here, feat. $SHPG, $NVO, $PHG and a #FierceMadness update. Issue | Follow @EmilyWFierce

> Boston Scientific buys endoscopic, ultrasound pancreatic treatment startup for $75M+. Article

> Israeli scientist developing novel wound-closing laser. Item

> Medtronic tries again in renal denervation after previous trial failure. More

Biotech News

@FierceBiotech: Index Ventures banks 650M euros for its new tech fund. Story | Follow @FierceBiotech

@JohnCFierce: Novartis steps in to help bankroll CRISPR-Cas9 pioneer Caribou. Article | Follow @JohnCFierce

@DamianFierce: Serious question: Is the $SRPT hold muzak an instrumental of "I'm all out of love / I'm so lost without you?" | Follow @DamianFierce

> Ipsen barrels into Boston with a new R&D hub and a Harvard pact. Story

> Sanofi adds a $120M computational drug design deal with Schrödinger. Article

> AstraZeneca razes R&D facilities in Delaware. Item

CRO News

> Piramal sells its CRO division to India's Indoco. Item

> WuXi and AstraZeneca roll toward Chinese approval with an arthritis drug. More

> Quintiles and Quest team up for lab testing with $575M JV. Report

> PPD's X-Chem flips some potential drugs to partner Navitor. Story

> Parexel buys an Indian CRO with an eye on drug safety. Article

Vaccines News

> Pfizer pulls vaccines sales business out of China. More

> Analysts: GSK shingles vaccine could steal market share from Merck's Zostavax. Story

> Sanofi, Merck win EMA nod for Gardasil 9. News

> GlaxoSmithKline and Merck Ebola vaccines succeed in Phase II Liberian trials. More

> GSK finally seals U.K. Bexsero deal for £20 per dose. Article

Pharma Manufacturing News

> Drug distributor goes 'Google' style with new facility. Article

> Catalent wraps another Asia-Pacific deal with Pharmapak buy. More

> Biocon's Syngene to build a plant in India. Story

> IPCA Labs' CRO in U.K. adding API space. Item

> Doctor to pay $2M, pleads guilty to dispensing foreign cancer drugs. Article

Pharma Asia News

> Infinity pulls trigger on Takeda oncology candidate option. More

> Takeda looks to settle thousands of Actos U.S. lawsuits for $2B. Article

> HK's Sihuan in partnership with Covance on drug development. Item

> India's Dr Reddy's snaps up some UCB brands in South Asia for $128.3M. Story

> Neurocrine and Mitsubishi Tanabe in license deal on Huntington's disease candidate. Report

And Finally... A small retrospective study found that adding an SGLT-2 diabetes therapy to a GLP-1 drug can result in additional weight loss for patients. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.